Tobacco Use Disorder Clinical Trial
Official title:
Clinical Trial of Two Medications on Smoking Cessation
Nicotine addiction is a serious health problem in the United States; 46 million people smoke cigarettes, and 70% of those are trying to quit. The nicotine patch and bupropion, a medication used to reduce nicotine cravings, are two commonly used smoking cessation aids. Both have been shown to reduce smoking rates, however, the effectiveness of combining the two treatments has not been widely examined. This study will evaluate the effectiveness of the nicotine patch combined with bupropion at reducing smoking rates among younger, low-income, and minority individuals.
Cigarette smoking poses a serious but preventable health risk. The negative health effects
of smoking are well-known, but the prevalence of cigarette smoking remains high in the
United States, particularly among younger people, people of lower socioeconomic status, and
minority groups. Nicotine replacement therapy, commonly known as the nicotine patch, has
been proven to be an effective treatment for reducing nicotine use. The nicotine patch
provides a measured dose of nicotine through the skin. By gradually lowering nicotine doses
over a period of time, individuals experience fewer nicotine cravings; the ultimate goal is
to stop using nicotine. Bupropion, a medication commonly used to treat depression, is also
used as a smoking cessation tool. It helps to control nicotine cravings. The majority of
studies on the nicotine patch and bupropion have been performed on older, white,
middle-class individuals; more research is needed to confirm the benefit of these treatments
in younger, low-income, and minority populations. While both the nicotine patch and
bupropion appear to be individually effective as smoking cessation aids, little is known on
the possible effectiveness of combining the two treatments. Because of the high relapse
rates in low-income and minority individuals, the combination of the nicotine patch with
bupropion may be particularly effective at reducing relapse rates in these individuals. The
purpose of this study is to evaluate the effectiveness of the nicotine patch and bupropion
at reducing smoking rates in younger, low-income, and minority individuals.
This 1-year study will enroll younger, low-income, and minority individuals who smoke.
Participants will be randomly assigned to one of the following three groups: 1) nicotine
patch plus placebo sustained-release bupropion; 2) placebo nicotine patch plus
sustained-release bupropion; or 3) nicotine patch plus sustained-release bupropion. At study
entry, participants will complete standardized psychological questionnaires to assess
depression levels and will undergo a physical exam and blood testing. Study visits will take
place at Weeks 5 and 11, Month 6, and Year 1. At each visit, questionnaires will be
completed, and smoking cessation rates will be assessed by self-report and verified by
saliva and exhaled carbon monoxide testing. In addition, all participants will take part in
a standardized behavioral smoking cessation program.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02432066 -
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
|
Phase 2 | |
| Completed |
NCT03960138 -
Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
|
N/A | |
| Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
| Completed |
NCT04646668 -
Comparative Abuse Liability Among African American and White Smokers
|
N/A | |
| Completed |
NCT02560324 -
Effect of Ramelteon on Smoking Abstinence
|
Phase 2 | |
| Completed |
NCT02347605 -
Medicinal Nicotine for Preventing Cue Induced Craving
|
N/A | |
| Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
| Completed |
NCT01625767 -
Tobacco Approach Avoidance Training for Adolescent Smokers-1
|
Phase 2 | |
| Terminated |
NCT01800500 -
Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
|
N/A | |
| Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
| Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
| Completed |
NCT00967005 -
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
|
Phase 2 | |
| Completed |
NCT01337817 -
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
|
Phase 1 | |
| Active, not recruiting |
NCT00751660 -
Screening Methods in Finding Lung Cancer Early in Current or Former Smokers
|
N/A | |
| Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
| Completed |
NCT00664261 -
Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking
|
N/A | |
| Completed |
NCT00218179 -
Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1
|
N/A | |
| Completed |
NCT00158145 -
Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2
|
Phase 2 | |
| Completed |
NCT01213524 -
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
|
Phase 2 |